Join us on March 7 for our Educated Patient Summit on Breast Cancer taking place in Miami, FL! 

To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Conor Killmurray
The Food and Drug Administration has granted approval to the combination of Nerlynx and Xeloda for the treatment of patients with advanced or metastatic HER2-positive breast cancer.
Ryan McDonald
Men who identify as gay or bisexual report having more skin cancers than those who identify as heterosexual. More frequent use of indoor tanning could be a cause, but researchers want to find out for sure.
Ryan McDonald
The combination of Keytruda plus chemoradiotherapy induced a ‘promising’ 12-month progression-free survival rate in patients with locally advanced non-small cell lung cancer.
Katie Kosko
Patients with the aggressive blood cancer can turn to immunotherapies like CAR-T cell therapy when disease recurs or becomes resistant.
Katie Kosko
Treatment for patients with bladder cancer is moving away from VEGF-targeted therapies toward immune checkpoint inhibition, according to one expert.
Conor Killmurray
From the first child born to a patient with cancer from an egg matured in a lab to women with breast cancer taking to the runway for New York Fashion Week, here’s what is making headlines in the cancer space this week.
Brielle Benyon
The Clinical Treatment Act was created to expand clinical trial access to patients insured by Medicaid.
Kristie L. Kahl
MK-6482 demonstrated an objective response rate of 24% among patients with advanced clear cell renal cell carcinoma, according to study findings presented at the 2020 Genitourinary Cancers Symposium.
Kristie L. Kahl
The Food and Drug Administration granted a priority review to the new drug application for lurbinectedin to treat patients with small cell lung cancer.
Kristie L. Kahl
After five years of follow-up, treatment with Opdivo in those with previously treated advanced or metastatic renal cell carcinoma induced superior survival outcomes.

Sign In

Not a member? Sign up now!
Continue without login